Zobrazeno 1 - 10
of 54
pro vyhledávání: '"C. J. A. Punt"'
Autor:
R. R. J. Coebergh van den Braak, S. ten Hoorn, A. M. Sieuwerts, J. B. Tuynman, M. Smid, S. M. Wilting, J. W. M. Martens, C. J. A. Punt, J. A. Foekens, J. P. Medema, J. N. M. IJzermans, L. Vermeulen
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background There are profound individual differences in clinical outcomes between colorectal cancers (CRCs) presenting with identical stage of disease. Molecular stratification, in conjunction with the traditional TNM staging, is a promising
Externí odkaz:
https://doaj.org/article/d6c7c6e7e2db4724b5be3c4143803535
Autor:
F. E. Buisman, M. Y. V. Homs, D. J. Grünhagen, W. F. Filipe, R. J. Bennink, M. G. H. Besselink, I. H. M. Borel Rinkes, R. C. G. Bruijnen, A. Cercek, M. I. D’Angelica, O. M. van Delden, M. L. Donswijk, L. van Doorn, P. G. Doornebosch, J. Emmering, J. I. Erdmann, N. S. IJzerman, C. Grootscholten, J. Hagendoorn, N. E. Kemeny, T. P. Kingham, E. G. Klompenhouwer, N. F. M. Kok, S. Koolen, K. F. D. Kuhlmann, M. C. Kuiper, M. G. E. Lam, R. H. J. Mathijssen, A. Moelker, E. Oomen-de Hoop, C. J. A. Punt, W. W. te Riele, J. M. L. Roodhart, R. J. Swijnenburg, W. Prevoo, P. J. Tanis, M. Vermaas, M. W. J. Versleijen, F. P. Veuger, M. J. Weterman, C. Verhoef, B. Groot Koerkamp
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Recurrences are reported in 70% of all patients after resection of colorectal liver metastases (CRLM), in which half are confined to the liver. Adjuvant hepatic arterial infusion pump (HAIP) chemotherapy aims to reduce the risk of
Externí odkaz:
https://doaj.org/article/d0f854d1c54447efb3a30f326aef6834
Autor:
M. Lamkaddem, M. A. G. Elferink, M. C. Seeleman, E. Dekker, C. J. A. Punt, O. Visser, M. L. Essink-Bot
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background Ethnic differences in colon cancer (CC) care were shown in the United States, but results are not directly applicable to European countries due to fundamental healthcare system differences. This is the first study addressing ethni
Externí odkaz:
https://doaj.org/article/15b1165c33864405926c7a9a80379465
Autor:
E. Van Cutsem, I. Danielewicz, M. P. Saunders, P. Pfeiffer, G. Argilés, C. Borg, R. Glynne-Jones, C. J. A. Punt, A. J. Van de Wouw, M. Fedyanin, D. Stroyakovskiy, H. Kroening, P. Garcia-Alfonso, H. Wasan, A. Falcone, R. Fougeray, A. Egorov, N. Amellal, V. Moiseyenko
Publikováno v:
British journal of cancer, 126(11), 1548-1554. Nature Publishing Group
Scientia
Scientia
Background Therapeutic options are limited in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy. The use of trifluridine/tipiracil plus bevacizumab (TT-B) in this setting was evaluated in the TASCO1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03af4faff5144bcdcf5517b7b9e24306
https://doi.org/10.1038/s41416-022-01737-2
https://doi.org/10.1038/s41416-022-01737-2
Autor:
E, Van Cutsem, I, Danielewicz, M P, Saunders, P, Pfeiffer, G, Argilés, C, Borg, R, Glynne-Jones, C J A, Punt, A J, Van de Wouw, M, Fedyanin, D, Stroyakovskiy, H, Kroening, P, Garcia-Alfonso, H, Wasan, A, Falcone, R, Fougeray, A, Egorov, N, Amellal, V, Moiseyenko
Publikováno v:
British journal of cancer. 126(11)
Therapeutic options are limited in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy. The use of trifluridine/tipiracil plus bevacizumab (TT-B) in this setting was evaluated in the TASCO1 trial; here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::63310fc54ca846256359e1c9d02978f3
https://pubmed.ncbi.nlm.nih.gov/35440667
https://pubmed.ncbi.nlm.nih.gov/35440667
Autor:
R. R. J. Coebergh Van Den Braak, S. Ten Hoorn, A. M. Sieuwerts, J. B. Tuynman, M. Smid, S. M. Wilting, J. W. M. Martens, C. J. A. Punt, J. A. Foekens, J. P. Medema, J. N. M. IJzermans, Vermeulen, L.
Additional file 1: Supplementary Table S1. Distribution of CMS per tumor stage in the total and individual cohorts. Supplementary Figure S1. Distribution of the molecular subtypes per tumor stage in the individual cohorts. Supplementary Figure S2. Ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bd1af1c3fc9f0bba7330f54d4cbe906
Autor:
E P, van der Stok, J, Huiskens, B, Hemmes, D J, Grünhagen, T M, van Gulik, C, Verhoef, C J A, Punt
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 160
Large multicentre randomised controlled trials (RCTs) in the Netherlands are increasingly being impeded by major differences between local approval procedures. However, no national agenda exists as yet to improve this situation. The existence of majo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b7e34b4ed919e8f9488a80b2c9f13416
https://pubmed.ncbi.nlm.nih.gov/27552934
https://pubmed.ncbi.nlm.nih.gov/27552934
Autor:
C. J. A. Punt, J. Tol
Publikováno v:
Targeted Oncology. 2:165-172
The introduction of inhibitors of signal transduction pathways has increased the therapeutic arsenal for patients with advanced colorectal cancer (ACC). Bevacizumab, a monoclonal vascular endothelial growth factor antibody, is currently part of the s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa3ddccc9342466b3de1dfb75b4aad9a
https://doi.org/10.1007/s11523-007-0052-7
https://doi.org/10.1007/s11523-007-0052-7
Autor:
E M V, de Cuba, P, Snaebjornsson, D A M, Heideman, N C T, van Grieken, L J W, Bosch, R J A, Fijneman, E, Belt, H, Bril, H B A C, Stockmann, E, Hooijberg, C J A, Punt, M, Koopman, I D, Nagtegaal, V H M, Coupé, B, Carvalho, G A, Meijer
Publikováno v:
International journal of cancer. 138(5)
Microsatellite instability (MSI) has been associated with favourable survival in early stage colorectal cancer (CRC) compared to microsatellite stable (MSS) CRC. The BRAF V600E mutation has been associated with worse survival in MSS CRC. This mutatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dd0c3a1152cbeb3285f6dc6536ff074b
https://pubmed.ncbi.nlm.nih.gov/26376292
https://pubmed.ncbi.nlm.nih.gov/26376292
Autor:
M Verseveld, E J R de Graaf, C Verhoef, E van Meerten, C J A Punt, I H J T de Hingh, I D Nagtegaal, J J M E Nuyttens, C A M Marijnen, J H W de Wilt, P J Tanis, G M J Bökkerink, H Rütten, P G Doornebosch, E J Derksen, R S Dwarkasing, A Cats, R A E M Tollenaar, H J T Rutten, J W A Leijtens, G P van der Schelling, A J ten Tije, G Lammering, G L Beets, T J Aufenacker, A Pronk, E R Manusama, C Hoff, A J A Bremers
Publikováno v:
British Journal of Surgery, 102(7), 853-860
British Journal of Surgery, 102(7), 853-860. Wiley
British journal of surgery, 102(7), 853-860. John Wiley and Sons Ltd
British Journal of Surgery, 102(7), 853-860. John Wiley & Sons Ltd.
British Journal of Surgery, 102, 7, pp. 853-60
British Journal of Surgery, 102, 853-60
British Journal of Surgery, 102(7), 853-860. Wiley
British journal of surgery, 102(7), 853-860. John Wiley and Sons Ltd
British Journal of Surgery, 102(7), 853-860. John Wiley & Sons Ltd.
British Journal of Surgery, 102, 7, pp. 853-60
British Journal of Surgery, 102, 853-60
Background This prospective multicentre study was performed to quantify the number of patients with minimal residual disease (ypT0–1) after neoadjuvant chemoradiotherapy and transanal endoscopic microsurgery (TEM) for rectal cancer. Methods Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cd4a212883f056875dcff882e93f718
https://doi.org/10.1002/bjs.9809
https://doi.org/10.1002/bjs.9809